Jorge da Silva
Co-Founder, Interim Chair of the Board & CEO

Good morning, good afternoon to all of those attending this MoonLake webcast. My name is Jorge Santos da Silva. I'm CEO and Chairman of the company. And I am accompanied here today by my co-founder and Chief Scientific Officer, Kristian Reich, and by our Chief Financial Officer, Matthias Bodenstedt.

In today's session, we're really going to focus on HS, our main indication in dermatology. We will start off with a brief introduction just to make sure that everybody is in the same page, but also to make sure that the key messages are delivered early on as they are very strong and important for the company and for sonelokimab. We will then spend some time and Kristian will take us through that. Looking at the final data of what is arguably the largest program in HS today. I remind everybody that this program is composed of 4 trials that will be important for the registration of the product, starting with a comparative trial, MIRA, where we compared ourselves to the standard of care Humira and placebos, the 2 large VELA studies, where we tested our main dose versus placebo over time.

And of course, a trial that is very dear to us, the VELA-TEEN trial, a trial that covered also adolescents first also in HS. Once we've been able to look at all this data together, I will take it back to recap how we're going to follow our label strategy and our BLA submission following all the conversations we've had with the FDA. And now in